Novartis is bolstering its leadership in the radiopharmaceutical space by partnering with US-based startup Ratio Therapeutics to develop a somatostatin receptor 2 (SSTR2) radiotherapeutic for cancer treatment.
As part of the agreement, Ratio stands to receive up to $745m in combined upfront and milestone payments, along with tiered royalties on sales. The collaboration focuses on preclinical research to identify an SSTR2-targeting development candidate, after which Novartis will take the lead on development, manufacturing, and commercialisation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
A protein overexpressed in various cancers, SSTR2 is a key target for therapies due to its role in enabling precise and targeted treatment. Novartis is already a key player in this field with its pioneering radiopharmaceutical Lutathera (lutetium Lu 177 dotatate), which also targets SSTR2. Acquired in the $3.9bn purchase of Advanced Accelerator Applications in 2017, Lutathera was the first radiopharmaceutical approved by the FDA and the EMA for treating neuroendocrine gastroenteropancreatic tumours.
This latest partnership follows a surge of investment within the radiopharmaceutical space. In May, Novartis acquired Mariana Oncology in a $1.75bn deal, inheriting the latter’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Meanwhile, other big pharma companies such as Bristol Myers Squibb (BMS) and Eli Lilly have also entered the arena, with acquisition deals worth $4.2bn and $1.4bn, respectively.
Ratio brings innovation to the table through its proprietary Trillium and Macropa platforms, which use alpha particles’ tumour-killing properties to develop tuneable radiopharmaceuticals. These platforms aim to expand the range of solid tumours that can be targeted. Earlier this year, Ratio secured $50m in Series B funding to accelerate the platforms’ development.
In the announcement accompanying the deal, Novartis’ president of biomedical research Fiona Marshall said: “Radioligand therapies hold transformative potential for certain forms of cancer, and Novartis is committed to maximising their impact by continually improving the benefit for patients.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataRadiopharmaceutical therapy – which involves targeting cancer cells with a radioactive drug consisting of a radioactive atom combined with a cell-targeting molecule – has seen substantial growth in recent years. Venture financing for innovative radiopharmaceutical drugs witnessed an increase from $63m in 2017 to over $400m in 2023 total deal value in the US, according to GlobalData’s Pharma Intelligence Center Deals Database.
GlobalData is the parent company of Pharmaceutical Technology.
